Nineteen patients received IOS-1002 as monotherapy, and 28 patients receive IOS-1002 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, pembrolizumab (Keytruda®). In the monotherapy arm, 6 out of 19 patients (32%) achieved Stable Disease, highlighting a favorable disease control rate. Besides very promising clinical benefit for patients, IOS-1002 shows a very favorable safety and tolerability profile without anti-drug antibodies. Identified biomarkers and patient response characteristics will guide patient stratification for the planned Phase Ib clinical trial, anticipated to start in the second half of 2026. ###About ImmunOs Therapeutics AGImmunOs Therapeutics AG leverages its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases.